Louisiana State Employees Retirement System Sells 2,200 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Louisiana State Employees Retirement System reduced its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 6.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,300 shares of the life sciences company’s stock after selling 2,200 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Integra LifeSciences were worth $587,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Blue Trust Inc. lifted its position in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. CWM LLC lifted its position in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 425 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in Integra LifeSciences during the second quarter valued at approximately $114,000. Northwest Investment Counselors LLC bought a new stake in Integra LifeSciences during the third quarter valued at approximately $73,000. Finally, EntryPoint Capital LLC lifted its position in Integra LifeSciences by 191.0% during the first quarter. EntryPoint Capital LLC now owns 4,580 shares of the life sciences company’s stock valued at $162,000 after purchasing an additional 3,006 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Up 3.3 %

Shares of NASDAQ IART opened at $24.91 on Wednesday. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $45.42. The firm’s fifty day moving average is $18.68 and its 200 day moving average is $24.41. The company has a market cap of $1.93 billion, a price-to-earnings ratio of 85.90, a PEG ratio of 0.66 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same period in the previous year, the firm earned $0.76 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. On average, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Morgan Stanley lifted their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. JMP Securities lowered their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Citigroup boosted their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Finally, Bank of America lowered their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.